ClinicalTrials.gov
public full text
Public Domain
Companion Pharmacogenetic Study to UMCC 9900/9901
The purpose is to examine the original breast tumor material to see how much of a metabolizing enzyme (CYP3A4) is present in tumor material. The researchers want to see if this is in any way associated with how the patient responded to docetaxel. They also want to examine the genes in the tumor that are responsible for the production of CYP metabolizing enzymes, to see if they are normal or if they have polymorphisms, or change compared to 'normal' CYP metabolizing enzymes.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- The Study Aims to Measure the Metabolome in Melanoma Patients Using NMR Spectroscopy and Gas Chromatography and to Analyse Differences Depending on the Course of the Disease.#829382
- The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing#1096134
- Position statement from the Italian Society of Human Genetics (SIGU) on the implementation of germline pharmacogenetic testing#202767
- Genetic Determinants of the Metabolism of Non-nucleoside Reverse Transcriptase Inhibitors#1246488
- Using Pharmacogenetics to Improve Treatment in Early-onset Diabetes#1113391
Record · ID 1309009
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive